Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.
about
Supramaximal dose of candesartan in proteinuric renal diseaseCombination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal functionAntihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemCardio classics revisited--focus on the role of candesartan.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials.TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 RatsThe Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney DiseaseEvidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.Therapeutic strategies to slow chronic kidney disease progression.Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelinesPreparing for the worst while hoping for the best: the relevance of hope in the heart failure illness trajectory.Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.Angiotensin blockade to reduce microvascular damage in diabetes mellitus.Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy.Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.Candesartan: widening indications for this angiotensin II receptor blocker?Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success.Direct Renin inhibitor: aliskiren in chronic kidney disease.A review of chemical therapies for treating diabetic hypertension.Blockade of the renin-angiotensin system for renal protection: from history to future perspectives.Future strategies to prevent renal microvascular disease complications in diabetes.Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients.Renin inhibition with aliskiren.2007 ESH‐ESC Guidelines for the management of arterial hypertension
P2860
Q24649685-199F107D-72A0-4540-B186-D6058C10F11CQ26795398-3EDBFECF-BD21-4A19-8587-AB59CE529B0AQ26865691-F8EBBAD9-8CCD-44FA-84A9-F01F175B338DQ34417462-F18D17F4-4A61-4E45-B642-83C1B05E38D1Q34604473-FF417ADA-CA94-46E5-8BB4-B29FD0FF7215Q35111064-F4BFA900-326B-462A-A5FF-B878835CA8EDQ35660077-11302041-43C6-4FA3-86EF-25F8454E6585Q35914820-7F26935C-EF76-4DB4-B154-1698481D98EDQ36384453-91946418-1EF3-4A57-80BA-B91079DE077AQ36510669-D94F4D71-B593-4F60-9A05-F27B1EA2F429Q36701736-D9526EF9-AF4A-4F34-B5F3-C191D842CBC6Q36815965-3C82E684-E7BB-4573-B154-790F9F580760Q36834059-7BB299F3-F70E-4CE4-A7C4-E85821D559C1Q36839029-4629ACB7-4CE9-4553-9875-7835E284A841Q37159292-4E7EAE10-CA11-4164-86D3-8EC7BAA43D23Q37369097-8DE3F6D7-92E7-4652-89BD-1117F6548A84Q37390013-D8404213-0768-4433-AB88-18079C28990FQ37415058-B7047E93-CCA3-4218-B3AC-A22CC1F0D150Q37477614-195BEAFE-AE39-44C3-B5F5-971EA0886CC3Q37534746-67425CFF-4758-455F-8E1C-BDD15AB00E9FQ37574913-503F9EAC-14A3-49D6-A5BD-3E7B998BB3A5Q38057913-B08E2472-C6EF-409D-B2B6-3743E7F67FB5Q38098186-91EDCF83-3C4E-4C3C-8EBD-0CCB402978F4Q39290260-7C2A2980-7147-473E-BB94-F898856F0303Q40133091-A107AAC4-9745-47C6-B556-4F939C565473Q40139541-AA06BC49-F371-42FA-8B33-5A9E392AF2F6Q41652967-3BA90D51-0173-4861-8005-BCEB7F1ADE75Q42421661-4C723F82-5CE1-4E3E-BD06-379050C8D03AQ43016390-7B98CF95-D294-4DA8-B5E4-36681A64E496Q43275293-FB9EF440-6BE4-4CC5-BB4A-66D60F43A1C8Q46727866-1B5EDEF9-6597-4BAD-BAF9-55B41E96DD80Q56970799-4CCED02C-0292-4703-BE6F-32F0C46C08E5
P2860
Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Additional antiproteinuric eff ...... randomized, prospective study.
@en
type
label
Additional antiproteinuric eff ...... randomized, prospective study.
@en
prefLabel
Additional antiproteinuric eff ...... randomized, prospective study.
@en
P2093
P356
P1476
Additional antiproteinuric eff ...... randomized, prospective study.
@en
P2093
Arnfried U Klingbeil
Christian Delles
Erwin H Fleischmann
Roland E Schmieder
Roland Veelken
P304
P356
10.1681/ASN.2005020138
P577
2005-08-24T00:00:00Z